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Abstract: Cannabidiol (CBD), a nonpsychoactive phytocannabinoid, has recently emerged as a po-
tential cytotoxic agent in addition to its ameliorative activity in chemotherapy-associated side ef-
fects. In this work, the potential interactions of CBD with docetaxel (DOC), doxorubicin (DOX), 
paclitaxel (PTX), vinorelbine (VIN), and 7-ethyl-10-hydroxycamptothecin (SN−38) were explored in 
MCF7 breast adenocarcinoma cells using different synergy quantification models. The apoptotic 
profiles of MCF7 cells after the treatments were assessed via flow cytometry. The molecular mech-
anisms of CBD and the most promising combinations were investigated via label-free quantification 
proteomics. A strong synergy was observed across all synergy models at different molar ratios of 
CBD in combination with SN−38 and VIN. Intriguingly, synergy was observed for CBD with all 
chemotherapeutic drugs at a molar ratio of 636:1 in almost all synergy models. However, discording 
synergy trends warranted the validation of the selected combinations against different models. En-
hanced apoptosis was observed for all synergistic CBD combinations compared to monotherapies 
or negative controls. A shotgun proteomics study highlighted 121 dysregulated proteins in CBD-
treated MCF7 cells compared to the negative controls. We reported the inhibition of topoisomerase 
II β and α, cullin 1, V-type proton ATPase, and CDK-6 in CBD-treated MCF7 cells for the first time 
as additional cytotoxic mechanisms of CBD, alongside sabotaged energy production and reduced 
mitochondrial translation. We observed 91 significantly dysregulated proteins in MCF7 cells treated 
with the synergistic combination of CBD with SN−38 (CSN−38), compared to the monotherapies. 
Regulation of telomerase, cell cycle, topoisomerase I, EGFR1, protein metabolism, TP53 regulation 
of DNA repair, death receptor signalling, and RHO GTPase signalling pathways contributed to the 
proteome-wide synergistic molecular mechanisms of CSN−38. In conclusion, we identified signifi-
cant synergistic interactions between CBD and the five important chemotherapeutic drugs and the 
key molecular pathways of the combination of CBD and CSN−38 in MCF7 cells. Further in vivo and 
clinical studies are warranted to evaluate the implementation of CBD-based synergistic adjuvant 
therapies for breast cancer. 
Keywords: cannabidiol; CBD; doxorubicin; docetaxel; paclitaxel; SN−38; vinorelbine; breast cancer; 
synergy; apoptosis; proteomics 
 
1. Introduction 
Medicinal cannabis and its secondary metabolites have garnered significant attention 
in recent years, and have been subject to extensive research and scrutiny [1–7]. From a 
medicinal and pharmaceutical standpoint, nonpsychoactive phytocannabinoids—such as 
cannabidiol (CBD)—are the most potentially beneficial components of cannabis’ chemical 
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space [2,8]. CBD has displayed a wide range of pharmacological activities in several pre-
clinical and clinical studies that enabled its potential application in inflammation, cancer, 
cardiovascular diseases, epilepsy, and neurodegenerative and psychiatric disorders [6,9–
18]. The US Food and Drug Administration (FDA) has approved Epidiolex® ® —a pure 
CBD formulation—for use in patients with Lennox–Gastaut syndrome or Dravet syn-
drome seizures [19]. Sativex® ®  (2.7 mg THC and 2.5 mg CBD per dose) has also been ap-
proved in around 30 countries for pain management in multiple sclerosis [18]. On a global 
scale, over 40 countries have approved medicinal marijuana/cannabis programmes. How-
ever, the Drug Enforcement Administration (DEA) has declared that CBD is a Schedule V 
banned substance, and its products must contain less than 0.1% ∆9-THC to be approved 
by the FDA [20]. The current legal status of CBD is neither clear nor harmonised world-
wide, although there are widespread medicinal, food, or cosmetic products that contain 
CBD [21,22]. Intriguingly, liquid chromatography coupled with mass spectrometry ena-
bles the subnanomolar detection and quantitation of cannabinoids in different biological 
matrices [23]. 
CBD displays anticancer potential, blocking cancer initiation, progression, and inva-
sion for various cancer types, including breast, lung, colon, prostate, brain, multiple my-
eloma, and skin cancers [6,7,9]. CDB, and the endocannabinoid system in general, have 
long been studied for their potential to treat cancer. Unlike the psychoactive cannabinoids, 
CBD has a comparatively lower affinity to both CB1 and CB2 receptors [24,25]. Neverthe-
less, it has been reported to act as a CB1 antagonist in murine brain tissue and vas def-
erens, or as an inverse agonist in human CB2 receptors [24,26]. Moreover, CBD interaction 
targets include 5-HT1A, GPR55, and PPAR-γ, in addition to TRPVs [27,28]. The basal res-
piration rate and ATP production in the gastric cancer cells were decreased by CBD, with 
suppressed proliferation and tumour growth, in a murine xenograft model [29]. CBD-in-
duced mitochondrial stress in MCF7 cells, with a modulated mitochondrial redox and dy-
namics, was recently reported [30]. These are all suggestive of CBD’s impacts on the mi-
tochondrial processes and energy production in cancer cells, where holistic multi-omics 
investigations are warranted in order to understand the underlying mechanisms. Other 
potential targets for CBD in cancers—such as cyclin-dependent kinases (CDK) and topoi-
somerases—are not well explored, despite the displayed selective inhibition of topoiso-
merase II by CBD derivatives such as HU-331 [31]. CBD’s anti-cancer mechanisms, its an-
tiproliferative and pro-apoptotic effects, and its inhibitory effects on cancer metastasis, 
invasion, and migration were summarised in recent reviews [6,7,9]. CBD is also involved 
in the regulation of reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, in-
flammation, and immunological modulation [6]. 
Breast cancer is the most common cancer type in women worldwide, with the highest 
regional incidence reported in Australia and New Zealand [32,33]. CBD was found to in-
hibit oestrogen-receptor-positive (ER+), -negative (ER−) or -triple-negative breast cancer 
cells (TNBC) in a dose-dependent manner, with relatively low IC50 values [6,34–39]. This 
suggests that breast cancer cells are sensitive to CBD, while non-transformed epithelial 
breast cells (MCF10A) are not significantly affected [10,28,39,40]. Interestingly, the admin-
istration of CBD in several clinical trials, as a single dose of 150–900 mg [41–49] or 50–1000 
mg/day for up to 13 weeks [50–53], showed overall good tolerability and safety profile, 
with mild side effects [54]. A variety of mechanisms for CBD’s antiproliferative effects 
have been reported, including autophagy, cell cycle arrest at the G1/S checkpoint, and 
apoptosis in MCF7, MDA-MB-231, and 4T1 breast cancer cells [34,35,39,55]. Recent studies 
have found that the antiproliferative effect of CBD in breast cancer cells was independent 
of endocannabinoid receptors (to some extent), mediated primarily through ROS-induced 
cell death [34,35,39,56,57]. CBD’s pro-apoptotic actions were attributed to the downregu-
lation of mTOR, AKT, 4EBP1, and cyclin D, as well as the overexpression of PPAR-γ 
[35,39], where CBD coordinated apoptosis and autophagy via Beclin-1 translocation and 
cleavage [39]. Furthermore, CBD inhibited the invasive and metastatic nature of aggres-
sive TNBC breast cancer by suppressing the activation of the EGF/EGFR pathway and its 
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downstream targets (AKT and NF-κB), along with Id-1 protein downregulation by ERK 
and ROS [34,36,37,55,56]. In comparison to daily administration, CBD administered three 
times per week boosted the longevity of mice while reducing the number of metastases 
[55,56]. CDB decreased TAM recruitment by downregulating CCL3, GM-CSF, and MIP-2, 
resulting in an overall reduction in angiogenesis [36]. Nevertheless, more research into 
the anticancer mechanisms of CBD at the proteome-wide level is needed in order to com-
prehensively understand and decode its complicated mechanisms to encourage future 
clinical trials. 
Based on the anticancer actions of CBD, it has been suggested that combinations of 
CBD and chemotherapeutic drugs may overcome cancer resilience by targeting various 
cancers’ pathophysiological components [58,59]. Synergistic combinations offer the use of 
lower doses with reduced side effects and curtailed drug resistance [60,61]. For instance, 
CBD inhibited exosome and microvesicle release, making breast (MDA-MB-231), prostate 
(PC3), and hepatocellular (HEPG2) cancer cells more sensitive to cisplatin [57]. It also syn-
ergistically improved the effects of paclitaxel (PTX) and doxorubicin (DOX) in both MCF7 
and MDA-MB-231 breast cancer cells [38]. Moreover, it reduced PTX-induced neurotoxi-
city via 5-HT1A receptors without affecting nervous system function or chemotherapeutic 
efficacy [62]. CBD amended DOX-induced cardiomyopathy by regulating the cardiac mi-
tochondrial functions in murine models [63]. Nevertheless, the synergistic interactions of 
CBD with chemotherapeutic drugs have not been thoroughly investigated. In particular, 
limited data are available on effective doses and drug interactions, and further research is 
required [64,65]. In addition, the utilisation of different synergy metrics is fundamental, 
as there is no consensus on a gold standard synergy quantification model [66–69]. 
In the present study, MCF7 cell line was selected, as it is the most studied human 
breast cancer cell line [70]. In addition, breast cancer chemotherapeutic agents with differ-
ent modes of action—taxane microtubule stabilisers (docetaxel, paclitaxel), anthracyclines 
(doxorubicin), microtubule-disruptive vinca-related alkaloids (vinorelbine), and topoiso-
merase I inhibitors (irinotecan metabolite = SN−38)—and their CBD combinations were 
studied. These chemotherapeutic agents represent the most common treatment options 
for stage I–IV breast cancer [71], along with other therapies, including hormonal therapy, 
radiotherapy, or surgery. We aimed to evaluate the synergistic interactions of CBD with 
chemotherapeutic drugs using different synergy quantitation metrics. The apoptotic pro-
files for the synergistic combinations were evaluated using flow cytometry. Furthermore, 
a shotgun proteomics study was conducted to decipher the proteome-level cytotoxic and 
synergistic mechanisms of CBD, and the most prominent (SN−38) synergistic combina-
tion. 
2. Results and Discussion 
2.1. Synergy Quantification of CBD and Standard Chemotherapeutic Drugs in MCF7 Human 
Breast Adenocarcinoma Cells 
Since there is no agreement on a benchmark synergy model [69] to decipher the com-
plex interactions between drugs, the exploration of different synergy models is advised. 
Therefore, multiple synergy quantification metrics were implemented to gain a compre-
hensive understanding of the potential synergistic interactions between CBD and the se-
lected chemotherapeutic drugs. The combination index (CI) model can be utilised for pair-
wise or higher order drug combinations in constant and non-constant ratio combinations 
[72]. This model was used to quantify the cytotoxic interactions against MCF7 cells after 
72 h of treatment. The CI < 1 and CI > 1 indicate synergism and antagonism, respectively, 
whereas additivity is indicated by CI = 1 [72]. CBD and the chemotherapeutic drugs were 
combined in molar ratios from 1431–18:1, respectively (Table 1). CompuSyn-calculated CI 
values at 50, 75, 90, 95, and 97% inhibitory concentrations are reported in Table 1. Each 
combination was denoted by an ID (e.g., CDOX19), where the last two digits indicate the 
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corresponding molar ratio of CBD and DOX, as reported in Table 1. In addition, a check-
erboard assay was used to combine the chemotherapeutic drugs with CBD in 1:10 and 1:2 
serial dilutions, respectively (Figure 1). Therefore, synergy quantification in the Loewe, 
ZIP, BLISS, HSA, and S synergy score models along the combination sensitivity score 
(CSS) were scrutinised over a broader range of anticancer concentrations in order to com-
prehensively understand the synergistic interactions of CBD with the chemotherapeutic 
drugs against MCF7 cells. 
Table 1. Drug interaction analysis of cannabidiol (CBD) and the chemotherapeutic combinations in MCF7 breast cancer 
cells. 
Combo ID, Molar Ratio 
CI Values at 
CSS S ZIP BLISS LOEWE HSA 
IC50 IC75 IC90 IC95 IC97 
CBD: Docetaxel           
CDOC19, 18:1 1.23 1.35 1.64 2.07 2.60 35.5 0.33 −11.81 −19.12 −6.84 −15.76 
CDOC28, 40:1 0.96 1.14 1.62 2.32 3.18 54.6 18.07 −10.9 −13.6 14.29 −9.42 
CDOC37, 68:1 0.70 0.91 1.46 2.27 3.27 41.33 3.96 −9.74 −11.35 −8.14 −7.08 
CDOC46, 106:1 0.49 0.70 1.23 2.04 3.03 49.82 13.09 −3.4 −5.61 −2.36 −1.38 
CDOC55, 159:1 0.45 0.70 1.35 2.33 3.54 52.65 14.33 −3.34 −4.58 −2.05 −0.8 
CDOC64, 238:1 0.50 0.86 1.80 3.20 4.94 51.66 12.22 −3.04 −4.2 −1.74 −0.29 
CDOC73, 371:1 0.38 0.72 1.61 2.95 4.61 52.44 13.36 −2.36 −3.69 −1.35 0.07 
CDOC82, 636:1 0.42 0.61 1.00 1.46 1.93 56.64 20.16 1.94 −0.1 1.86 3.4 
CDOC91, 1431:1 0.48 0.73 1.17 1.65 2.12 56.04 20.19 1.96 −1.08 0.16 2.06 
CI to DC - - - - - 55.50 18.89 −8.41 −7.93 −1.46 −0.65 
Checkerboard - - - - - 72.91 −11.77 1.76 −5.07 −4.17 −0.66 
Selected dose  
(39.75, 0.5 µM) 
- - - - - - - 28.12 21.45 24.27 46.02 
CBD: Doxorubicin           
CDOX19, 18:1 1.17 1.16 1.15 1.14 1.14 64.78 46.12 6.07 4.52 −5.24 1.62 
CDOX28, 40:1 1.12 1.11 1.10 1.10 1.09 66.93 46.23 3.32 1.97 −9.04 0 
CDOX37, 68:1 1.07 1.06 1.05 1.05 1.05 66.94 43.69 0.18 −1.53 −10.92 −2.66 
CDOX46, 106:1 1.42 1.41 1.40 1.39 1.38 65.5 42.45 0.61 −1.64 −11.27 −2.78 
CDOX55, 159:1 1.34 1.33 1.32 1.31 1.31 24.4 1.7 −13.69 −46.05 −55.66 −48.18 
CDOX64, 238:1 1.27 1.26 1.25 1.25 1.25 69.85 45.41 4.15 2.24 −6.37 0.99 
CDOX73, 371:1 1.20 1.19 1.19 1.18 1.18 73.33 48.85 6.67 5.38 −2.87 4.15 
CDOX82, 636:1  1.13 1.13 1.12 1.12 1.12 75.33 52.37 10.19 9.06 0.67 7.38 
CDOX91, 1431:1 1.07 1.06 1.06 1.06 1.06 76.85 55.09 9.89 8.72 −2.69 6.75 
CI to DC - - - - - 70.24 53.04 4.96 4.05 −5.43 2.21 
Checkerboard - - - - - 54.90 −5.31 1.04 −1.05 −9.15 −4.31 
Selected dose  
(38.42, 0.2 µM) 
- - - - - - - 32.52 25.65 15.16 31.53 
CBD: Paclitaxel           
CPTX19, 18:1 1.50 1.61 1.89 2.35 2.95 35.94 0.09 −12.32 −20.86 −20.59 −19.3 
CPTX28, 40:1 0.91 1.04 1.40 2.00 2.78 42.63 5.16 −7.42 −12.28 −11 −9.74 
CPTX37, 68:1 0.70 0.85 1.31 2.05 3.03 40.73 2.11 −8.38 −11.49 −10.07 −8.88 
CPTX46, 106:1 0.48 0.63 1.09 1.83 2.82 50.48 12.66 −2.18 −5.93 −4.42 −3.42 
CPTX55, 159:1 0.37 0.54 1.04 1.85 2.93 55.54 16.97 −0.14 −3.26 −2.93 −1.55 
CPTX64, 238:1 0.37 0.59 1.24 2.32 3.75 51.98 11.68 −1.04 −4.26 −3.37 −1.96 
CPTX73, 371:1 0.34 0.61 1.41 2.73 4.49 52.76 12.71 −0.76 −3.19 −2.35 −1.01 
CPTX82, 636:1 * 0.30 0.62 1.57 3.14 5.24 59.16 21.67 4.4 2.03 2.33 3.84 
CPTX91, 1431:1 * 0.33 0.80 2.21 4.56 7.68 59.28 23.01 3.81 1.2 1.2 2.66 
CI to DC - - - - - 57.70 21.51 −6.44 −8.30 −3.69 −3.53 
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Checkerboard - - - - - 53.78 −31.41 −5.35 −10.85 −7.90 −6.63 
Selected dose  
(64.6, 0.1 µM) 
- - 0.68 - - - - ~2.98 ~−1.69 ~6.1 ~1.95 
CBD:SN38            
CSN19, 18:1 1.77 5.14 18.44 51.56 115.29 40.24 13.73 −0.43 −3.87 −3 −1.38 
CSN28, 40:1 0.65 0.86 1.49 2.52 3.84 48.26 20.38 1.13 −0.58 1.23 2.95 
CSN37, 68:1 0.57 0.76 1.33 2.19 3.23 45.18 15.31 −2.32 −4.31 −2.18 −0.62 
CSN46, 106:1 * 0.47 0.59 0.95 1.44 1.98 50.63 21.35 1.96 0.13 2.04 3.69 
CSN55, 159:1 0.47 0.60 0.94 1.37 1.82 50.13 19.75 1.08 −0.83 −0.05 1.7 
CSN64, 238:1 0.45 0.60 0.97 1.40 1.85 49.6 18.07 0.23 −1.72 0.05 1.64 
CSN73, 371:1 ** 0.81 0.66 0.61 0.60 0.59 52.98 21.84 1.83 0.38 1.99 3.57 
CSN82, 636:1 ** 0.81 0.71 0.68 0.67 0.67 59.38 29.68 5.05 3.67 4.45 6.4 
CSN91, 1431:1 ** 0.92 0.93 0.91 0.91 0.90 58.73 29.9 3.43 2.21 2.79 4.66 
CI to DC - - - - - 48.39 23.86 2.37 1.35 3.58 4.46 
Checkerboard - - - - - 75.94 1.36 0.31 −3.24 −3.09 −0.08 
Selected dose 
(42.45, 0.11 µM) 
- 0.66 - - - - - 14.55 23.86 31.38 33.57 
CBD: Vinorelbine           
CVIN19, 18:1 1.30 1.39 1.64 2.02 2.53 31.94 −1.9 −9.19 −16.9 −16.72 −15.15 
CVIN28, 40:1 1.03 1.18 1.58 2.25 3.12 37.98 2.98 −8.44 −12.37 −12.2 −10.12 
CVIN37, 68:1 0.71 0.86 1.30 2.02 2.96 41.71 5.92 −6.9 −8.99 −7.59 −5.91 
CVIN46, 106:1 0.56 0.74 1.26 2.12 3.25 44.84 9.79 −4.31 −6.29 −5.35 −3.24 
CVIN55, 159:1 0.46 0.67 1.27 2.26 3.58 50.93 14.65 −1.54 −3.63 −3.13 −1.06 
CVIN64, 238:1 0.45 0.72 1.52 2.84 4.58 49.75 12.98 −2.21 −5.08 −3.64 −1.84 
CVIN73, 371:1 0.33 0.59 1.36 2.63 4.32 52.5 16.13 0.16 -2.16 −1.01 1.06 
CVIN82, 636:1 * 0.32 0.65 1.65 3.30 5.49 55.57 21.19 3.31 1.6 1.94 4.38 
CVIN91, 1431:1 ** 0.73 0.60 0.56 0.55 0.55 56.32 25.34 5.55 3.36 2.56 5.09 
CI to DC - - - - - 57.45 23.54 −5.89 −6.49 −1.64 −0.70 
Checkerboard - - - - - 56.45 −30.43 −1.79 −6.39 −4.94 −4.07 
Selected dose  
(42.4, 0.1 µM) 
- ~0.62- - - - - - 18.29 28.44 43.26 48.43 
CI = combination index; CI to DC = all combined responses from CI model combinations were analysed via DrugComb 
server; CSS = combination sensitivity score; IC = inhibitory concentration killing the corresponding percentage of MCF7 
cells; HSA = highest single agent model; ZIP = zero interaction potency model; ** = synergistic combinations in all models 
and inhibitory concentrations; * = synergistic combinations in all models and most effective doses; ~ = approximate score 
considered. Potential synergistic combinations with CI < 0.7 or synergy score > 1.5 in Loewe, HSA, ZIP, and Bliss models, 
or > 20 in the S model, are bold formatted. Potential effective combinations (CSS > 55) are bold formatted. Synergy metrics 
listed for the selected doses are derived from CI to DC. 




Figure 1. Dose–response and Loewe synergy quantitation of cannabidiol (CBD) combinations with the chemotherapeutic 
drugs against MCF7 cells in a checkerboard assay (n = 3). 
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A strong synergy was observed in different synergy models for the CDB combined 
with SN−38 (CSN91, CSN82, and CSN73) and vinorelbine (CVIN91). These combinations, 
unlike CPTX or CDOC, showed increased synergy in the CI model, with increased cell 
growth inhibition (Figure 2B), which is favoured for any anticancer treatment, where any 
antagonistic behaviour at a low fraction affected (Fa < 0.5 = 50% growth inhibition) will 
not be alarming. CBD and SN−38 combinations with a molar ratio of 1431, 636, or 371 to 1 
displayed CI values of 0.9–0.93, 0.67–0.81, and 0.60–0.81, respectively, at the IC50 to IC97 
modelled inhibitory concentrations. These combinations displayed synergistic scores in 
all DrugComb synergy models tested (Loewe, Bliss, HSA, ZIP, and S) when the same re-
sponse data were imported to the DrugComb webserver. Moreover, CVIN91 (molar ratio 
of 1431:1 of CBD:VIN) showed a CI value of 0.55–0.73, with positive synergy scores in all 
DrugComb models. In addition, CVIN82 displayed synergy in all DrugComb models, 
with synergistic CI values of 0.32 and 0.65 at IC50 and IC75, respectively. Interestingly, all 
CBD chemotherapeutic combinations at a molar ratio of 636:1 were synergistic in the 
Loewe, Bliss, HSA, ZIP, and S models, in agreement with the CI model at different inhib-
itory concentrations. Nevertheless, discording interactions were observed for the Bliss 
model of DOC and the CI model of DOX (Figure 2B), together with the CI values at some 
inhibitory concentrations for DOC, DOX, PTX, and VIN (Table 1). Both checkerboard and 
CI design data reanalysed in DrugComb concurred on the captured synergy of around 39 
µM CBD with various concentrations of different drugs (Figures 1 and 2). All of the IC50 
values for the different combinations and monotherapies in the CI design are listed in 
Table S1. Discording CompuSyn- and GraphPad-calculated IC50 values were observed—
particularly for the standard chemotherapies, despite the same data having been imple-
mented. These findings should be considered while using only CompuSyn for synergy 
evaluation. 




Figure 2. Most synergistic chemotherapeutic cannabidiol (CBD) combinations against MCF7 cells: (A) Loewe synergy quan-
titation of selected synergistic CBD combinations with standard chemotherapeutic agents (molar ratio of 636:1). (B) Combi-
nation index plots of the most synergistic combinations. Fa = fraction affected (% cell growth inhibition, where 1 = 100%). 
Figure 3 and Table S2 show the Pearson and Spearman correlation matrices as linear 
and nonparametric rank correlation measurements, respectively, for different synergy 
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quantification metrics and CSS. A non-significant weak correlation of the Loewe, Bliss, 
HSA, S, and Zip models with the CI model was indicated by the Pearson and Spearman 
correlation coefficients, except for the Loewe and HSA models, which were weakly and 
negatively correlated with the CI model at IC50 (Pearson r −0.45, −0.39, respectively; p < 
0.05). The same trend was observed for the CSS and S models’ Spearman correlation with 
the CI model at high inhibitory concentrations (IC90–IC97). The negative correlation dis-
played the different scaling, where the synergistic score of the CI model should be < 0, and 
that for the DrugComb synergy metrics should be > 0. However, moderate-to-strong Pear-
son and Spearman correlations were observed among the DrugComb synergy models and 
CSS (0.7–0.99, p < 0.05), except for Loewe with the CSS, S, and ZIP models (Pearson r = 0.5, 
0.29, and 0.52, respectively; p < 0.05) and HSA with the S synergy model (Pearson r = 0.56). 
Taken together, different synergistic interactions could have been drawn, implementing 
different models—particularly the CI model versus others. Notably, various synergy met-
rics—including Loewe, ZIP, HSA, and Bliss—displayed a moderate correlation with 
strong disagreement instances when calculated for the O’Neil anticancer combination da-
taset (22,737 unique combinations) [67,69,73]. Moreover, substantial disagreements were 
reported when correlating synergy scores originating from different datasets [67]. Thus, 
the selection of synergistic doses needs to be validated against different models. 
Unlike synergy, which captures the drug interactions, the combination sensitivity 
calculates the efficacy of the combined drugs, and its negligence may lead to biased syn-
ergistic combinations [74]. The relative IC50 value and the area under the drug combina-
tion dose-response curve were utilised to derive the CSS, which was presented as a robust 
metric for efficacy quantification of drug combinations [75]. Table 1 summarises the com-
bined sensitivity scores for the combinations of CBD with the chemotherapeutic drugs 
tested via checkerboard assay, or upon reprocessing of CI model data via DrugComb and 
their aggregated data (CI to DC). Notably, promising CSS values were observed for the 
synergistic combinations against different study designs. The highest CSS (>70) values 
were displayed for SN−38 and DOC combinations in the checkerboard assay, and DOX in 
the CI to DrugComb models. Considerably elevated CSS values were noticed for DOX 
combinations (CDOX19, CDOX28, CDOX37, CDOX64, and CDOX73), along with positive 
synergy scores in the ZIP, Bliss, and HSA synergy metrics, despite the marginally syner-
gistic to weak antagonistic CI values (Table 1). 
 
Figure 3. Correlation matrix of different synergy metrics and combination sensitivity scores (CSSs) using (A) Pearson and 
(B) Spearman correlation coefficients. CI = combination index derived from Chou–Talalay model; IC = inhibitory concen-
tration killing the corresponding percentage of MCF7 cells. Colour indicates the correlation coefficient along with negative 
correlations in blue and positive correlations in red, with the size being directly proportional to statistical confidence based 
on p-values. 
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Previously, synergistic CBD interactions with DOX and PTX were studied against 
MCF7 and MDA-MB-231 cells in the CI model. A limited range of responses (total of nine 
doses), resulting from mixing three fixed doses of CBD with DOX (20, 1, and 0.1 uM) and 
PTX (0.5, 0.1, and 0.01 uM), were examined [38]. The molar ratio ranges from 20–2000 and 
0.5–200 of CBD to 1 of PTX or DOX, respectively, were also explored in MCF7 cells [38]. 
Our findings are partially in agreement with the latter study in some synergy models, but 
we considered a broader range of responses (54 and 36 for our CI and checkerboard de-
signs, respectively) in different synergy models, together with CSS calculations. Interest-
ingly, CBD was previously reported to ameliorate DOX-induced cardiomyopathy via 
modulating cardiac mitochondrial functions such as complex I and complex II activities 
in mice [63,76]. In addition, CBD—or its combination with Δ9THC—reduced the PTX-in-
duced neuropathic pain in mice without affecting the nervous system function or PTX 
efficacy [62,77]. Collectively, the cardioprotective and pain relief effects of CBD, along 
with its synergistic interactions with DOX or PTX, warrant further studies for its potential 
implementation in clinical practice. 
CBD has been reported to potentiate DOC-inhibitory effects in LNCaP and DU-145 
xenografts in vivo, and against LNCaP, 22RV1, DU-145, and PC-3 cells in vitro [78]. Inter-
estingly, the coadministration of medicinal cannabis herbal tea did not affect the pharma-
cokinetics of irinotecan (and its SN−38 metabolite) and DOC [79]. Nevertheless, the po-
tential synergistic interactions of CBD with DOC, VIN, and SN−38 have not previously 
been studied. The synergistic interactions of DOC, VIN, and SN−38 with CBD found in 
the current study require further in vivo investigations to evaluate the enhanced chemo-
therapeutic effects where dose reduction of chemotherapy may be expected. 
In the present study, selected doses of combined CBD and chemotherapeutic drugs 
were validated against different models, including CI and DrugComb synergy metrics, 
with at least 90% inhibition of MCF7 cells. For DrugComb synergy models, both checker-
board design data and the combined dose responses of different combinations (CXYZ19 
to CXYZ91) were considered for the selection of the synergistic doses. These synergistic 
doses were further utilised in the subsequent flow cytometry and shotgun proteomics 
studies. 
2.2. Flow Cytometric Analyses of Apoptosis in MCF7 Human Breast Adenocarcinoma Cells 
Using Annexin V-CF Blue and 7-Aminoactinomycin D (7AAD) 
The apoptotic profiles of MCF7 cells were evaluated using flow cytometry after 24 h 
of treatment with CBD, chemotherapeutic agents, or their combinations. The chemother-
apeutic drugs (DOC, DOX, PTX, SN38, and VIN) and their most synergistic combinations 
with CBD were evaluated at the doses indicated in Table 1. A concurrent evaluation of 
apoptotic and necrotic MCF7 cells was carried out to detect whether the most synergistic 
combination had any enhanced apoptotic effects compared to monotherapy (Table S3). 
After 24 h, significant differences in the live, early or late apoptotic, total apoptotic, and 
necrotic cell populations were observed in the negative controls, monotherapies, and com-
bined treatments in pairwise comparisons via two-way ANOVA and Tukey’s test for mul-
tiple comparisons correction (p < 0.05, n = 3) (Figures 4, 5 and S1, and Table S3). 
CBD stimulated programmed cell death in the MDA-MB-231 breast cancer cells, with 
regulated crosstalk between apoptosis and autophagy [39]. In both the T-47D and MDA-
MB-231 breast cancer cells, CBD treatment coordinated an interplay between PPAR-γ, 
mTOR, and cyclin D1 that favours apoptotic induction [35]. In the present study, CBD 
alone (38.42–64.6 µM) significantly reduced the live population of MCF7 cells from 
around 92% to 78.74–32.37% (p < 0.001), in a dose-dependent manner. The total apoptotic 
MCF7 cells were significantly increased from 5.94% to 15.38–58.94% by CBD in different 
concentrations (p < 0.0001) compared to the negative controls (Figures 4B and 5B; p = 
0.0058 for 38.42 µM CBD). However, different CBD doses significantly increased necrosis 
in MCF7 cells (p < 0.01), from 1.4% to 8.69%, with the highest CBD concentration (64.60 
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µM). Altogether, a significant 3–11-fold increase in the number of apoptotic cells was ob-
served for different CBD doses in MCF7 cells compared to the untreated control cells, with 
a decreased living cell percentage and a slight increase in the number of necrotic cells 
(0.29–7.29%). 
Similarly, a significant reduction in the number of live cells, and increased numbers 
of apoptotic and necrotic cells, were observed for DOC (0.5 µM) and VIN (0.1 µM) as 
monotherapies (p < 0.0001 in comparison to the untreated MCF7 cells; Figures 4A,E and 
5A,E). PTX (0.1 µM) showed the same trend, except with a non-significant difference for 
necrotic cells (p = 0.58). A substantial increase in necrotic cells (~20-fold change compared 
to the controls; p < 0.0001) was observed for 0.2 µM DOX (Figures 4B and 5B). SN−38 
showed a weak decrease in the number of living cells, but its effect on apoptosis was not 
statistically significant at the currently selected dose of 0.11 µM (Figures 4D and 5D). 
A significant decrease in the live MCF7 cell population, with enhanced apoptosis, 
was observed for all of the synergistic CDB combinations, compared to monotherapies or 
negative controls (p < 0.0001), except for apoptotic cell percentage of CDOX compared to 
CBD or DOX, which was slightly higher, with p = 0.0003 and 0.001, respectively (Figures 
4, 5 and S1, Table S3). To this end, CBD enhanced the apoptotic activity of the studied 
chemotherapeutic drugs, which consequently contributed to the overall synergistic activ-
ity. For the following section, a shotgun proteomics discovery study was conducted to 
decipher the cytotoxic molecular mechanisms of CBD, and its possible synergistic mech-
anisms with SN−38 against MCF7 cells. 




Figure 4. Flow cytometric assessment of the apoptotic profiles of MCF7 cells after 24 h of treatment with cannabidiol, 
chemotherapeutic drugs, and their synergistic combinations (A–E). The images are representative of three separate exper-
iments. CBD = cannabidiol: DOC = docetaxel: DOX = doxorubicin: PTX = paclitaxel: SN−38: VIN = vinorelbine. (A) CDOC 
= CBD + DOC, (B) CDOX = CBD + DOX, (C) CPTX = CBD + PTX, (D) CSN–38 = CBD + SN–38, (E) CVIN = CBD + VIN. Cells 
were treated with the monotherapies, combinations, and vehicle control (0.5% DMSO), and detected using antibodies 
against Annexin V-CF Blue and the reporter 7AAD after 24 h of treatment. Raw data are available in Table S3. 




Figure 5. Cell percentage analysis of MCF7 cells after 24 h of treatment with cannabidiol, chemotherapeutic drugs, and 
their synergistic combinations (A-E). CBD = cannabidiol: DOC = docetaxel: DOX = doxorubicin: PTX = paclitaxel: SN−38: 
VIN = vinorelbine. (A) CDOC = CBD (39.75 µM) + DOC (0.5 µM), (B) CDOX = CBD (38.42 µM) + DOX (0.2 µM), (C) CPTX 
= CBD (64.60 µM) + PTX (0.1 µM), (D) CSN−38 = CBD (42.45 µM) + SN−38 (0.11 µM), (E) CVIN = CBD (42.4 µM) + VIN (0.1 
µM). Superscript letters indicate statistical significance derived from two-way ANOVA and Tukey’s multiple comparisons 
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2.3. Bottom-Up Label-Free Quantification Proteomics Study of MCF7 Cell Lysates after 
Treatment with CBD or Its SN−38 Synergistic Combination 
A shotgun proteomics study of MCF7 cells treated with 42.45 µM CBD, 0.11 µM 
SN−38, and their synergistic combination (CSN−38) was performed, with relative quanti-
fication, implementing the Hi-N method. The expressed proteins in CBD-treated MCF7 
cells were analysed in pairwise comparisons to the control group to trace for the difference 
in the proteome-wide dysregulated expressions that may be associated with the cytotoxic 
effects of CBD. To highlight the possible CSN−38 synergistic mechanisms, the differen-
tially expressed proteins in the combination-treated cells were analysed in pairwise com-
parison to the monotherapies. Among the total 3569 identified proteins, 1256 and 758 were 
found to be significantly different in CBD vs. Control and CSN−38 vs. monotherapies, 
respectively, with p and Q values ≤ 0.05 (Q-values are the adjusted p-values, and are de-
rived based on the optimised false discovery rate (FDR) approach). Figure 6 displays the 
quality control metrics and overlapped proteins among different experimental groups. 
Decent tryptic digestion could be speculated with minimal missed cleavages, and most of 
the peptides were eluted in the 3rd and 4th quartiles of the LC run. In addition, the pep-
tides with an absolute mass error of 20 ppm were disregarded based on the mass error 
distribution of the identified peptides (Figure 6A). The peptide counts, unique peptide 
counts, m/z, confidence scores, statistics, and fold change (FC) calculations are listed in 
Supplementary File 2. 
2.3.1. Proteome-Wide Elucidation of the Cytotoxic Effects of CBD in MCF7 Cells: Pilot 
Shotgun Proteomics Study 
The differentially expressed proteins in CBD-treated MCF7 cells, compared to the 
controls, were selected implementing p- and Q-values of ≤ 0.01 alongside an absolute FC 
≥ 2 (absolute log2 FC ≥ 1) cutoff. A total of 25 upregulated and 96 downregulated proteins 
were identified in CBD-treated cells (Tables 2 and 3, and Supplementary File 2 (CBD vs. 
control sheet)). These 121 dysregulated proteins represent the proteome-level variance ac-
quired upon CBD treatment. Therefore, these proteins may reflect the possible underlying 
mechanisms of its cytotoxic effects in MCF7 cells. 
STRING [80], Reactome [81], g:Profiler [82], and IMPaLA [83] overrepresentation 
analyses identified a subset of downregulated proteins encoding genes such as NDUFV1, 
NDUFB11, NDUFB10, NDUFS1, NDUFS2, and NDUFS8. These proteins were involved in 
complex I biogenesis, respiratory electron transport, mitochondrial ATP synthesis, the cit-
ric acid (TCA) cycle, oxidative phosphorylation, and retrograde endocannabinoid signal-
ling, together with COX6B and ATP6V0A2, for all of the aforementioned processes except 
for retrograde endocannabinoid signalling (Table 3, Figure 7, and Supplementary File 2, 
ORA_Enrich. of CBD vs. C sheet). 
Aerobic respiration occurs exclusively in the mitochondria of the eukaryotic cells and 
starts with glycolysis and the TCA cycle; followed by complexes I–IV, which form the 
electron transport chains (ETC) within the inner membrane of the mitochondria [84,85]. 
Complex I is the largest complex of the mitochondrial ETC, offering approximately 40% 
contribution of the redox-driven proton pump necessary for ATP production in the mito-
chondria [86]. Notably, complex I is required for biosynthesis and redox regulation during 
cancer cell growth, resistance to cell death, and metastasis [86]. CBD’s paradoxical regu-
latory effects on mitochondrial functions were recently reviewed in brain tissue, isolated 
mitochondria, and hippocampal cells [87]. CBD (4 µM) was previously found to signifi-
cantly undermine the basal respiration rate and ATP production in gastric cancer cells 
with suppressed proliferation and tumour growth in xenografted mice [29]. A similar 
trend was observed in the HCT116 and DLD-1 colorectal cancer cells (CRC) with Noxa- 
and ROS-dependent apoptosis [88]. 




Figure 6. Label-free quantification proteomics study of cannabidiol (CBD) synergistic combination with SN−38 in MCF7 
cells. (A) Overview of quality control metrics for the label-free quantification proteomics study showing peptides and 
protein counts, peptide charges, missed cleavage (approximately 70% of the identified peptides showed zero missed cleav-
age), most of the peptides eluted in the 3rd and 4th quartiles of the LC run, peak width, identified peptides per proteins, 
and mass errors proportions in the identified peptides. (B) Venn diagrams of the overlapped identified proteins’ counts 
in the differently treated groups. CSN−38 = synergistic combination of CBD and SN−38; control = vehicle (0.5% DMSO)-
treated MCF7 cells. 




Figure 7. Differentially expressed proteins in cannabidiol (CBD)-treated MCF7 cells compared to controls, and the corre-
sponding overrepresented pathways. (A) Volcano plot with an absolute log2 fold change ≥ 1 and p-value ≤ 0.05 cutoff, for 
the identified proteins in CBD-treated cells, together with selected proteins’ expression summary compared to the con-
trols. (B) STRING network of the 121 differentially expressed proteins (fold change ≥ 2; p and Q values ≤ 0.01) in the 
cannabidiol-treated MCF7 cells compared to the controls. The minimum required interaction score was 0.40 (medium 
confidence), and red, green, blue, purple, light blue, and black interaction lines indicate the presence of fusion, neighbour-
hood, co-occurrence, experimental, database, and co-expression evidence, respectively. The disconnected nodes were hid-
den in the network. (C) Overrepresented pathways using g:Profiler for the differentially expressed proteins (fold change 
≥ 2; p and Q values ≤ 0.01) in the cannabidiol-treated MCF7 cells compared to the controls (1 = oxidative phosphorylation; 
2 = retrograde endocannabinoid signalling; 3 = complex I biogenesis; 4 = respiratory electron transport; 5 = mitochondrial 
translation initiation; 6 = the citric acid (TCA) cycle and respiratory electron transport; 7 = mitochondrial complex I assem-
bly model OXPHOS system; 8 = mitochondrial inner membrane; 9 = mitochondrial protein-containing complex; 10 = mi-
tochondrial electron transport; NADH to ubiquinone; 11 = aerobic electron transport chain; 12 = mitochondrial ATP syn-
thesis-coupled electron transport; 13 = NADH dehydrogenase (quinone) activity; 14 = NADH dehydrogenase (ubiquinone) 
activity; 15 = NADH dehydrogenase activity). CC: cellular components; MF: molecular function; BP: biological processes; 
REAC: Reactome database; WP: Wiki Pathways. 
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V-ATPase inhibitors were found to facilitate the control of the tumour microenviron-
ment, with reduced tumour acidity and metastasis, along with the prevention of chemo-
resistance [89]. 
In light of the aforementioned downregulated proteins and their involvement in the 
biological processes, CBD-mediated apoptosis and cytotoxicity in MCF7 cells may involve 
a decreased mitochondrial energy production via the downregulation of complex I- and 
IV-related proteins (FC = −8.44 to −1.15). In addition, CBD can potentially reduce the tu-
mour acidic microenvironment and metastasis by downregulating V-type proton ATPase 
(FC = −1.16). Here, CBD was reported for the first time among V-ATPase inhibitors. 
In our study, CBD repressed the mitochondrial translation in MCF7 cells. Briefly, the 
initiation, elongation, and termination of the mitochondrial translation were also over-
represented in recruiting the 121 dysregulated proteins in different platforms (Table 3, 
Figure 7, and Supplementary File 2). The downregulated PTCD3-, MRPS22-, MRPS34-, 
MRPL38-, MRPS31-, and MRPL23-encoded proteins (FC = −2.27 to −1.57) were involved 
in the inhibited mitochondrial translation. Mitochondrial translation inhibition has been 
suggested as a therapeutic strategy for ovarian cancer [90] and human acute myeloid leu-
kemia [91]. Altogether, CBD mediated the mitochondrial power outage alongside the in-
hibited mitochondrial translation in MCF7 breast cancer cells. 
Expression dysregulation was observed for proteins involved in DNA synthesis, the 
cell cycle, mitosis checkpoints, and G1/S transition, such as the upregulated CDC25B-, 
NHP2-, and PSMD9-encoded proteins and the downregulated RRM2-, CUL1-, MCM2-, 
UBE2C-, and CDK6-encoded proteins (Tables 2 and 3, Figure 7, and Supplementary File 
2). In addition, D-type cyclins and their binding partner kinases are important regulators 
of cell cycle progression, tumour development, and proliferation in breast cancer and nor-
mal breast epithelial cells [92]. Multiple mitogenic signalling pathways regulate and in-
fluence CDK4/6 and cyclin D activity, including oestrogen receptors and receptor tyrosine 
kinase (RTK), as well as the PI3K–AKT–mTOR or RAS–RAF–MEK–ERK pathways [92]. 
Of note, CDK6 knockdown was shown to overcome the abemaciclib resistance in MCF7 
cells [93]. In this context, CBD-mediated inhibition of CDK-6 in MCF7 cells (FC = −1.96) 
could be utilised to enhance the sensitivity of CDK4/6 inhibitors such as abemaciclib, pal-
bociclib, and ribociclib for the treatment of hormone-receptor-positive breast cancer. Ad-
ditionally, the downregulated cullin 1 (FC = −1.97), CUL1-encoded protein may be corre-
lated with curtailed proliferation, migration, and invasion of breast cancer [94–96]. Fur-
thermore, CBD-downregulated minichromosome maintenance proteins (MCM), such as 
the DNA replication licensing factor MCM2, may elucidate the effects of CBD on replica-
tion and cell cycle development, while a recent meta-analysis postulated the overexpres-
sion of MCM2-7 as a predictive biomarker of poor cancer prognosis [97]. Similarly, a 
growing body of evidence supports the oncogenic potential of the ubiquitin-conjugating 
enzyme E2C (UBE2C)’s overexpression in breast cancer, which is linked to the loss of 
BRCA1 function and induced chemical resistance in MCF7 and MDA-MB-231 cells [98]. 
Notably, the enhanced effects of radiation, doxorubicin, tamoxifen, and letrozole were 
observed in breast cancer cells upon the downregulation of UBE2C [99]. Taken together, 
the CBD-mediated downregulation of MCM2- and UBE2C-encoded proteins contributed 
to the overall cytotoxicity of CBD, along with the suppressed proliferation, migration, and 
invasion via the declined expression of cyclin-dependent kinase 6 (CDK6) and cullin 1 in 
MCF7 cells. 
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Table 2. Significantly upregulated proteins in cannabidiol-treated MCF7 cells. 
Uniprot ID * 
HGNC Gene 
ID 
Protein Name Log2 Fold Change 
P04733 MT1F Metallothionein-1F 7.03 
A0A0J9YWD4 RIMS2 Regulating synaptic membrane exocytosis protein 2 5.80 
Q8WX94 NLRP7 NACHT_ LRR and PYD domains-containing protein 7 5.75 
P02795 MT2A Metallothionein-2 3.78 
Q9Y2Z9 COQ6 Ubiquinone biosynthesis monooxygenase COQ6 2.60 
A6NCE7 MAP1LC3B2 Microtubule-associated proteins 1A/1B light chain 3 beta 2 1.68 
E9PRY0 EIF3M Eukaryotic translation initiation factor 3 subunit M 1.66 
Q9NX24 NHP2 H/ACA ribonucleoprotein complex subunit 2 1.51 
Q5JPF3 ANKRD36C Ankyrin repeat domain-containing protein 36C 1.50 
A0A0B4J1X2 CACNA1G Voltage-dependent T-type calcium channel subunit α-1G 1.48 
P12645 BMP3 Bone morphogenetic protein 3 1.45 
Q9BQ39 DDX50 ATP-dependent RNA helicase DDX50 1.44 
P08910 ABHD2 Monoacylglycerol lipase ABHD2 1.40 
Q8TCU6 PREX1 
Phosphatidylinositol 3_4_5-trisphosphate-dependent Rac 
exchanger 1 protein 
1.35 
Q3KQV9 UAP1L1 UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 1.34 
Q14139 UBE4A Ubiquitin conjugation factor E4 A 1.26 
M0QZQ3 SPTBN4 Spectrin beta chain 1.26 
F5GZS6 SLC3A2 4F2 cell-surface antigen heavy chain 1.25 
P35527 KRT9 Keratin_ type I cytoskeletal 9 1.23 
F5GX23 PSMD9 26S proteasome non-ATPase regulatory subunit 9 1.22 
Q5XKE5 KRT79 Keratin_ type II cytoskeletal 79 1.07 
Q9NRV9 HEBP1 Heme-binding protein 1 1.05 
H0YMI4 USP3 Ubiquitin carboxyl-terminal hydrolase 1.01 
B4DIG0 CDC25B Protein-tyrosine-phosphatase 1.00 
P29992 GNA11 Guanine nucleotide-binding protein subunit alpha-11 1.00 
* Significantly upregulated proteins in 42.45 µM CBD-treated MCF7 cells (p and Q ≤ 0.01 alongside Progenesis QIP-calcu-
lated maximum fold change ≥ 2 = log2 fold change ≥ 1) compared to the vehicle-treated control cells. 
Table 3. Significantly downregulated proteins in cannabidiol-treated MCF7 cells. 
Uniprot ID * HGNC Gene ID Protein Name 
Log2 Fold 
Change 
P02538 KRT6A Keratin 6A −28.33 
E9PC85 LRRK2 Leucine-rich repeat kinase 2 −30.08 
Q9BRK5 SDF4 45 kDa calcium-binding protein −10.86 
P28331 NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa subunit_ mitochondrial −8.44 
K7EPA3 TMEM161A Transmembrane protein 161A −7.83 
Q14249 ENDOG Endonuclease G_ mitochondrial −7.53 
Q9H501 ESF1 ESF1 homologue −4.39 
Q9NRY5 FAM114A2 Protein FAM114A2 −4.24 
C9J2C7 NT5C1B-RDH14 NT5C1B-RDH14 readthrough −3.95 
Q9NX14 NDUFB11 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 
11_ mitochondrial 
−3.49 
A0A3B3ISF0 LARP1B La-related protein 1B −3.35 
Q9UP79 ADAMTS8 A disintegrin and metalloproteinase with thrombospondin motifs 8 −3.34 
Q8IYA6 CKAP2L Cytoskeleton-associated protein 2-like −3.31 
P60602 ROMO1 Reactive oxygen species modulator 1 −3.26 
P55317 FOXA1 Hepatocyte nuclear factor 3-alpha −3.25 
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Q96G01 BICD1 Protein bicaudal D homologue 1 −3.23 
O43291 SPINT2 Kunitz-type protease inhibitor 2 −3.21 
O00762 UBE2C Ubiquitin-conjugating enzyme E2 C −3.04 
O00291 HIP1 Huntingtin-interacting protein 1 −2.83 
Q02818 NUCB1 Nucleobindin-1 −2.81 
E9PJC6 AHNAK Neuroblast differentiation-associated protein AHNAK −2.58 
Q2TV78 MST1L Putative macrophage stimulating 1-like protein −2.51 
A0A6Q8PFY3 FANCD2 Fanconi anemia group D2 protein −2.45 
A0A0U1RR07 SYTL2 Synaptotagmin-like protein 2 −2.43 
Q8IVV2 LOXHD1 Lipoxygenase homologuey domain-containing protein 1 −2.31 
Q9BUB7 TMEM70 Transmembrane protein 70_ mitochondrial −2.28 
Q8TCT8 SPPL2A Signal peptide peptidase-like 2A −2.27 
Q96DV4 MRPL38 39S ribosomal protein L38_ mitochondrial −2.27 
Q9Y646 CPQ Carboxypeptidase Q −2.23 
Q15036 SNX17 Sorting nexin-17 −2.22 
O75306 NDUFS2 
NADH dehydrogenase [ubiquinone] iron–sulfur protein 2_ 
mitochondrial 
−2.17 
G3V0I5 NDUFV1 NADH dehydrogenase [ubiquinone] flavoprotein 1_ mitochondrial −2.12 
A0A590UJ21 CUL1 Cullin-1 −1.97 
Q00534 CDK6 Cyclin-dependent kinase 6 −1.96 
Q9P1A6 DLGAP2 Disks large-associated protein 2 −1.95 
K7EJV0 SEPTIN9 Septin-9 −1.92 
E7EN73 KIAA0319L Dyslexia-associated protein KIAA0319-like protein −1.92 
C9JJ19 MRPS34 28S ribosomal protein S34_ mitochondrial −1.92 
Q92665 MRPS31 28S ribosomal protein S31_ mitochondrial −1.88 
Q96C01 FAM136A Protein FAM136A −1.86 
Q16540 MRPL23 39S ribosomal protein L23_ mitochondrial −1.83 
A0A2R8YGD3 RAPGEF2 Cyclic nucleotide ras GEF −1.81 
G8JLA1 RDH13 Retinol dehydrogenase 13 −1.80 
P82650 MRPS22 28S ribosomal protein S22_ mitochondrial −1.76 
O00217 NDUFS8 
NADH dehydrogenase [ubiquinone] iron–sulfur protein 8_ 
mitochondrial 
−1.75 
Q9Y2Z2 MTO1 Protein MTO1 homologue_ mitochondrial −1.68 
A0A0A0MRM2 NRAP Nebulin-related-anchoring protein −1.64 
Q9UKX2 MYH2 Myosin-2 −1.64 
Q6X4W1 NSMF 
NMDA receptor synaptonuclear signaling and neuronal migration 
factor 
−1.62 
O75363 BCAS1 Breast carcinoma-amplified sequence 1 −1.62 
O94913 PCF11 Pre-mRNA cleavage complex 2 protein Pcf11 −1.62 
Q92823 NRCAM Neuronal cell adhesion molecule −1.60 
Q96EY7 PTCD3 
Pentatricopeptide repeat domain-containing protein 3_ 
mitochondrial 
−1.57 
Q6ZXV5 TMTC3 Protein O-mannosyl-transferase TMTC3 −1.53 
Q6IBS0 TWF2 Twinfilin-2 −1.50 
Q9NY74 ETAA1 Ewing’s tumour-associated antigen 1 −1.50 
Q8N961 ABTB2 Ankyrin repeat and BTB/POZ domain-containing protein 2 −1.42 
A0A1B0GU86 ACY1 N-acyl-L-amino-acid amidohydrolase −1.42 
P55011 SLC12A2 Solute carrier family 12 member 2 −1.42 
H7BYU6 ZNF521 Zinc finger protein 521 −1.38 
P04181 OAT Ornithine aminotransferase_ mitochondrial −1.36 
Q8N565 MREG Melanoregulin −1.33 
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Q14802 FXYD3 FXYD domain-containing ion transport regulator 3 −1.33 
Q7L2E3 DHX30 ATP-dependent RNA helicase DHX30 −1.32 
Q12767 TMEM94 Transmembrane protein 94 −1.31 
Q8N0X2 SPAG16 Sperm-associated antigen 16 protein −1.30 
P14854 COX6B1 Cytochrome c oxidase subunit 6B1 −1.30 
Q92820 GGH Gamma-glutamyl hydrolase −1.28 
M0QY24 ZNF546 Zinc finger protein 546 −1.26 
Q02880 TOP2B DNA topoisomerase 2-beta −1.25 
P50579 METAP2 Methionine aminopeptidase 2 −1.23 
Q8NEZ3 WDR19 WD repeat-containing protein 19 −1.23 
G5E9Z9 LRP2BP LRP2 binding protein_ isoform CRA_a −1.22 
Q8TDY2 RB1CC1 RB1-inducible coiled-coil protein 1 −1.22 
H0Y5K5 ERGIC3 Endoplasmic reticulum-Golgi intermediate compartment protein 3 −1.20 
Q9H869 YY1AP1 YY1-associated protein 1 −1.20 
A7XYQ1 SOBP Sine oculis-binding protein homologue −1.18 
P49006 MARCKSL1 MARCKS-related protein −1.18 
H3BLV9 SRPK1 SRSF protein kinase 1 −1.17 
Q9Y487 ATP6V0A2 V-type proton ATPase 116 kDa subunit a2 −1.16 
Q9BZG8 DPH1 2-(3-amino-3-carboxypropyl)histidine synthase subunit 1 −1.15 
H3BV16 NDUFB10 Complex I-PDSW −1.15 
Q99797 MIPEP Mitochondrial intermediate peptidase −1.15 
O95294 RASAL1 RasGAP-activating-like protein 1 −1.14 
P23921 RRM1 Ribonucleoside-diphosphate reductase large subunit −1.14 
Q8IVG5 SAMD9L Sterile alpha motif domain-containing protein 9-like −1.13 
P31350 RRM2 Ribonucleoside-diphosphate reductase subunit M2 −1.13 
Q8WVV9 HNRNPLL Heterogeneous nuclear ribonucleoprotein L-like −1.08 
A0A2R8YET2 PRRC2C Protein PRRC2C −1.07 
Q9HCM1 RESF1 Retroelement silencing factor 1 −1.07 
F8VWW7 SPRYD3 SPRY domain-containing protein 3 −1.06 
P54296 MYOM2 Myomesin-2 −1.03 
Q86XE3 MICU3 Calcium uptake protein 3_ mitochondrial −1.02 
P49736 MCM2 DNA replication licensing factor MCM2 −1.01 
Q9H4E5 RHOJ Rho-related GTP-binding protein RhoJ −1.01 
Q9HAZ2 PRDM16 Histone-lysine N-methyltransferase PRDM16 −1.00 
* Significantly downregulated proteins in 42.45µM CBD-treated MCF7 cells (p and Q ≤ 0.01 alongside maximum Progen-
esis QIP-calculated maximum fold change ≥2 = log2 fold change ≤−1) compared to the vehicle-treated control cells. 
Topoisomerase II (TOP2) inhibitors are potent chemotherapeutic drugs that regulate 
DNA replication [100]. DNA Topoisomerase IIβ and α (TOP2B and TOP2A) were signifi-
cantly downregulated in CBD-treated MCF7 cells compared to the controls, with FC = 
−1.25 and −0.72, respectively (Table 3 and Supplementary File 2). Previously, CBD deriv-
atives such as HU-331 displayed selective inhibition to topoisomerase II isoforms via non-
competitive inhibition of their ATPase activity [31]. Here, we report the inhibition of TOP2 
isoforms in CBD-treated MCF7 cells for the first time, as an additional cytotoxic mecha-
nism, along with the aforementioned downregulation of CDK-6-, MCM2-, and UBE2C-
encoded proteins. In addition, the mitochondria-related mechanisms were underlined, in-
cluding sabotaged energy production and mitochondrial translation. 
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2.3.2. Proteome-Wide Elucidation of Synergistic Mechanisms of SN−38 Synergistic Com-
bination with CBD in MCF7 Cells: Pilot Shotgun Proteomics Study 
The differentially expressed proteins in the synergistic CBD and SN−38 combination-
treated cells, compared to the monotherapies, were selected implementing p- and Q-val-
ues of ≤ 0.01 alongside a maximum FC ≥ 2 (absolute log2 FC ≥ 1) cutoff. A total of 5 upreg-
ulated and 31 downregulated proteins were identified in CBD-treated cells. These 36 
dysregulated proteins represent the proteome-level variance acquired upon CSN−38 
treatment (Table 4). Therefore, they may reflect the possible underlying synergistic mech-
anisms of action against MCF7 breast adenocarcinoma cells. Relaxed p- and Q-values of ≤ 
0.05, together with the same FC cutoff, identified 91 dysregulated proteins recruited in 
further pathway analyses, where no significant pathway enrichment was identified im-
plementing the 36 most significant proteins. 
A subset of downregulated proteins encoding genes such as CCT7, ATM, and 
MAP3K4, alongside the overexpressed MAPK15 involved in the positive regulation of te-
lomere maintenance by telomerase, was identified upon the recruitment of the 91 dysreg-
ulated proteins (Supplementary File 2, CSN38 vs. Monotherapies sheet) in STRING [80] 
and g:Profiler [82] overrepresentation analyses (Figure 8). 
We observed overexpressed chaperonin-containing TCP-1s (CCTs), such as CCT7, 
which was shown to be involved in breast cancer progression, associated with poor over-
all survival in breast cancer patients, and was recently speculated as a potential breast 
cancer therapeutic target and valuable prognostic marker [101]. In addition, ATM ser-
ine/threonine kinase encoded by ATM is involved in DNA repair, cell cycle arrest, and 
apoptosis as activated and recruited upon DNA double-strand breaks (DSBs) [102,103]. 
ATM gene mutations result in ataxia–telangiectasia, where disrupted recognition and re-
pairs of DNA double-strand breaks (DSBs) take place, with increased risk of cancer 
[104,105]. CSN−38 significantly downregulated both T-complex protein 1 subunit eta 
(CCT7) and ATM in MCF7 cells (−1.78 and −2.84 FC, respectively) compared to the mono-
therapies, where impaired DNA DSB repairs and tumour progression could be antici-
pated through the synergism of CBD and SN−38. 
Mitogen-activated protein kinase 4 (MAP3K4) was also downregulated and was 
highlighted as a potential radiation response biomarker in both post- and preoperative 
settings in breast cancer patients [106]. Unlike healthy tissue, tumours increase extracel-
lular acidification as cancer cells ferment glucose with increased lactate production, and 
maintain the same level of mitochondrial respiration even in the presence of oxygen, 
which was hypothesized by Otto Warburg as a hallmark of cancer [107,108]. Interestingly, 
the MAP3K4 downregulation inhibited the Warburg effect by regulating lactate secretion 
and lactate receptor expression through the HER2/HER3 signalling pathways in MCF7 
cells [109]. In our study, CSN−38 significantly decreased the expression of MAP3K4 (FC 
−1.15, Q = 0.025; Supplementary File 2, CSN38 vs. Monotherapies sheet), which might in-
hibit the migration and extracellular acidity of MCF7 cells. In addition to MAP3K4, 
MAPK15 was also involved in the MAPK signalling pathway and was overexpressed in 
the CSN38-treated cells compared to the monotherapies. Increased migration of breast 
and lung cancer cells was reported earlier upon the downregulation of MAPK15 (alias 
ERK8), which acts as a negative regulator of cell migration and O-glycosylation of N-
acetylgalactosamine (GalNAc) [110]. O-GalNAc glycosylation in the endoplasmic reticu-
lum was reported as a driving mechanism of cancer invasiveness [111]. Based on the cur-
rent findings, the CSN−38 treatment might inhibit the invasiveness and migration of 
MCF7 cells by increasing MAPK15 expression (FC 1.1). 




Figure 8. Differentially expressed proteins in synergistic CBD and SN−38 combination-treated MCF7 cells (CSN−38) com-
pared to the monotherapies, and the corresponding overrepresented pathways. (A) Volcano plot with an absolute log2 
fold change ≥ 1 and p-value ≤ 0.05 cutoff of the identified proteins in the CSN−38-treated cells, together with the selected 
proteins’ expression summary compared to the monotherapies. (B) STRING network of the 91 differentially expressed 
proteins (fold change ≥ 2; p and Q values ≤ 0.05). The minimum required interaction score was 0.40 (medium confidence), 
and red, green, blue, purple, light blue, and black interaction lines indicate the presence of fusion, neighbourhood, co-
occurrence, experimental, database, and co-expression evidence, respectively. The disconnected nodes were hidden in the 
network. (C) Overrepresented pathways using g:Profiler for the differentially expressed proteins (fold change ≥ 2; p and 
Q values ≤ 0.05). 
Several proteins involved in the cell cycle, EGFR1, metabolism of proteins, TP53 reg-
ulation of DNA repair, death receptor signalling, and RHO GTPase signalling pathways 
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were significantly over-represented or enriched (p ≤ 0.05) in IMPaLA or Reactome anal-
yses upon recruiting the 91 dysregulated proteins in the combination-treated MCF7 cells. 
However, a high false discovery rate or Q value ≥ 0.05 was observed for these pathways 
(Supplementary File 2, ORA_Enrich of CSN38 vs. Monotherapies sheet). All of the in-
volved proteins identified in Reactome-enriched pathways were downregulated (en-
coded by ELL, ATM, POLR2H, PCF11, SNAPC3, ABR, PREX1, IRAK1, SPPL2A, NGEF, 
ITGAL, KLKB1, TMEM87A, ELAC2, UBE2C, ARID1A, NUP93, WDR5, ZNF546, ZNF521, 
CCT7, ACY1, AJUBA, NRCAM, and CBL), except for FBXW10-encoded protein, which was 
overexpressed. 
The most downregulated proteins in the combination-treated MCF7 cells were breast 
carcinoma-amplified sequence 1, DnaJ homologue subfamily C member 11, NADH:ubiq-
uinone oxidoreductase subunit A2, and ubiquitin-conjugating enzyme E2 C (FC −27.75, 
−24.86, −5.01, and −4.84, respectively), compared to the monotherapies. The synergistic 
combination significantly diminished the expression of breast carcinoma-amplified se-
quence 1—a breast cancer oncogenic protein that is linked to mammary tumourigenesis 
[112]. Complex I-related proteins (NDUFA2) and UBE2C-encoded protein are discussed 
in Section 2.3.1. DnaJ homologue subfamily C member 11 is a heat shock protein, recently 
found to be upregulated in breast cancers such as basal, luminal B, and HER2 breast can-
cer subtypes, and downregulated in other tumour types; however, its functional role in 
breast cancer has not yet been deciphered [113,114]. 
Three downregulated proteins encoded by ABR, PREX1, and NGEF (FC −1.84, −1.06 
and −1.0, respectively) were involved in death receptor signalling, p75NTR receptor-me-
diated signalling (NGFR), and cell death signalling via NRAGE, NRIF, and NADE, as 
identified in Reactome enrichment analysis (p-values 2.82 × 10−3, 8.25 × 10−4 and 4.51 × 10−3, 
respectively). IRAK1-encoded interleukin 1 receptor-associated kinase 1 was also signifi-
cantly involved in death receptor signalling, p75NTR receptor-mediated signalling, and 
p75NTR signals through NF-κB, as identified by Reactome and IMPaLA. IRAK1 silencing 
in MCF7 cells was previously reported to decrease invasion, proliferation, and migration, 
with enhanced sensitivity to PTX [115]. Aggressive growth, PTX resistance, and metastasis 
were also reported in triple-negative breast cancer cells mediated via IRAK1 overexpres-
sion [116]. Recently, a large study including 1085 breast cancer patients showed a positive 
correlation of decreased IRAK1 expression and reduced tumour size following neoadju-
vant chemotherapy [117]. A synergistic effect was also noticed through the downregu-
lated phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (PREX1, FC -
1.06). Briefly, decreased MCF7 viability was reported for PREX1 loss by positive feedback 
to upstream phosphatidylinositol 3-kinase (P13K) activators [118]. In addition, a positive 
correlation was found between PREX1 overexpression and poor prognosis in breast can-
cer patients via neuregulin–ErbB signalling [119]. Similarly, the neuronal guanine nucle-
otide exchange factor (NGEF) overexpression was correlated with tumour progression 
and metastasis, including in breast carcinomas [120]; therefore, its decreased expression 
in the synergistic combination-treated cells will contribute to the overall synergistic effect 
of CBD with SN−38 against MCF7 cells. 
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Description Log2 Fold Change * 
Downregulated proteins 
O75363 BCAS1 Breast carcinoma-amplified sequence 1 −27.75 
Q9NVH1 DNAJC11 DnaJ homologue subfamily C member 11 −24.68 
O00762 UBE2C Ubiquitin-conjugating enzyme E2 C −4.84 
O94913 PCF11 Pre-mRNA cleavage complex 2 protein Pcf11 −4.32 
A0A1B0GU86 ACY1 N-acyl-L-amino-acid amidohydrolase −4.16 
A0A2R8YGD3 RAPGEF2 Cyclic nucleotide ras GEF −2.48 
Q9P1V8 SAMD15 Sterile alpha motif domain-containing protein 15 −2.44 
Q8TDI0 CHD5 Chromodomain-helicase-DNA-binding protein 5 −2.42 
K7ER88 ACAA2 3-Ketoacyl-CoA thiolase_ mitochondrial (Fragment) −2.05 
P20701 ITGAL Integrin alpha-L −2.01 
A0A0D9SG95 CCT7 T-complex protein 1 subunit eta −1.78 
P03952 KLKB1 Plasma kallikrein −1.72 
Q92823 NRCAM Neuronal cell adhesion molecule −1.63 
O75582 RPS6KA5 Ribosomal protein S6 kinase alpha-5 −1.56 
Q6UXG2 ELAPOR1 
Endosome/lysosome-associated apoptosis and autophagy 
regulator 1 
−1.56 
Q5H9M0 PWWP3B PWWP domain-containing DNA repair factor 3B −1.47 
P55199 ELL RNA polymerase II elongation factor ELL −1.46 
Q9NPB8 GPCPD1 Glycerophosphocholine phosphodiesterase GPCPD1 −1.46 
Q2TV78 MST1L Putative macrophage stimulating 1-like protein −1.42 
A0A0U1RQX8 CBL E3 ubiquitin-protein ligase CBL −1.35 
Q6P4H8 ATPSCKMT ATP synthase subunit C lysine N-methyltransferase −1.34 
O14513 NCKAP5 Nck-associated protein 5 −1.33 
Q8WVV9 HNRNPLL Heterogeneous nuclear ribonucleoprotein L-like −1.32 
A0A2R8Y5P9 SHROOM3 Protein Shroom3 −1.22 
O43303 CCP110 Centriolar coiled-coil protein of 110 kDa −1.18 
Q9C091 GREB1L GREB1-like protein −1.13 
Q9BQ52 ELAC2 Zinc phosphodiesterase ELAC protein 2 −1.12 
A0A075B757 NBPF14 Neuroblastoma breakpoint family member 14 −1.11 
O14497 ARID1A AT-rich interactive domain-containing protein 1A −1.10 
Q96C90 PPP1R14B Protein phosphatase 1 regulatory subunit 14B −1.04 
Q6IEG0 SNRNP48 U11/U12 small nuclear ribonucleoprotein 48 kDa protein −1.00 
Upregulated proteins 
O94973 AP2A2 AP-2 complex subunit alpha-2 1.20 
O14949 UQCRQ Cytochrome b-c1 complex subunit 8 1.11 
A0A1C7CYZ1 MAPK15 Mitogen-activated protein kinase 15 (Fragment) 1.10 
Q5T9A4 ATAD3B ATPase family AAA domain-containing protein 3B 1.03 
P49189 ALDH9A1 4-Trimethylaminobutyraldehyde dehydrogenase 1.01 
*: p and Q ≤ 0.01 alongside maximum Progenesis QIP-calculated fold change ≥ 2 (absolute log2 fold change ≥ 1), compared 
to the monotherapies (CBD and SN−38); CSN38: the synergistic combination of 42.45 µM cannabidiol and 0.11 µM SN−38. 
PCF11-encoded protein was among the top downregulated proteins in the combina-
tion-treated MCF7 cells, with a fold change of −4.32. PCF11 downregulation is associated 
with favourable outcomes in neuroblastoma patients [121], but its functional role in breast 
carcinoma is still unexplored. However, it was found to be involved in the alternative 
polyadenylation (APA), causing three prime untranslated region (3′ UTR) shortening of 
mRNA by cancer-specific ubiquitin ligase [17]. Additionally, aminoacylase 1 (ACY1) was 
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also significantly downregulated (FC −4.16) in the CSN38-treated MCF7 cells compared 
to the monotherapies. ACY1 is responsible for amino acid deacylation during protein deg-
radation and has been reported to be upregulated in colorectal cancer patients and 
HCT116 cells, promoting tumour progression [122,123]. ACY1 has been proposed as a tu-
mour suppressor in small-cell lung cancer, renal cell carcinoma, and hepatocellular cancer 
cells, as its decreased expression in these cells may accumulate acylated peptide growth 
factors [124–126]. ACY1 was also downregulated in MCF7 cells treated with 17β-estradiol, 
suggesting its role as a tumour suppressor in oestrogen-dependent breast carcinomas, but 
further studies are needed in order to evaluate its clinical relevance in breast cancer [127]. 
The downregulation of integrin subunit alpha L, nucleoporin 93, and signal peptide 
peptidase-like 2A encoded by the ITGAL, NUP93, and SPPL2A genes (FC −2.01, −2.30, and 
−2.0, respectively) contributed to the synergistic mechanisms of CBD and SN−38 against 
MCF7 cells. Briefly, ITGAL overexpression was reported in lymph node metastases of 
breast cancer patients, compared to the primary breast tumours, highlighting its role in 
breast cancer metastasis [128]. On the other hand, the overexpression of nucleoporin 93—
a nuclear envelope protein—enhanced the migration and invasion of the triple-negative 
and claudin-low breast cancer cells alongside metastasis in animal models [129,130]. 
Moreover, the signal peptide peptidase was highly induced in breast and lung cancer cell 
lines, and its role in tumour progression is anticipated via FKBP8 degradation [131]. Col-
lectively, in addition to its synergistic activity against MCF7-related breast adenocarcino-
mas, these findings indicate the potential therapeutic role of CSN−38 against other breast 
cancer subtypes, including triple-negative breast cancers. However, further studies in-
volving a wide range of in vitro and in vivo breast cancer models are necessary in order 
to develop potential CBD-based adjuvants for breast cancer in the future. Moreover, CBD 
significantly synergized the SN−38- mediated inhibition of DNA topoisomerase 1 (TOP1) 
in MCF7 cells (FC −1; p = 0.01 and Q = 0.03), which contributed to the overall synergy 
between CBD and SN−38 (Figure 8A). 
3. Material and Methods 
3.1. Chemicals and Drug Preparation 
DOC, DOX, PTX, VIN, SN38, and CBD of > 98% purity were purchased from Sigma-
Aldrich, NSW, Australia. A freshly prepared stock solution in dimethyl sulfoxide (DMSO) 
of 1 and 158.998 mM was prepared for chemotherapeutic drugs and CBD, respectively. 
CBD was combined with drugs in nine different ratios (1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 
and 9:1, v/v) for combination index (CI) analyses. Moreover, 50, 1, 2, 1, and 2 mM stock in 
DMSO of DOC, DOX, PTX, VIN, and SN38, respectively, were prepared for synergy stud-
ies in a checkerboard design. 
3.2. Breast Adenocarcinoma Cell Line Culture Conditions 
MCF7 human breast adenocarcinoma cells were obtained from the American Type 
Culture Collection (ATCC: Manassas, VA, USA). Dulbecco’s modified Eagle’s medium 
(DMEM; Lonza, NSW, Australia) with 4.5 g/L glucose, L-glutamine, and sodium pyruvate 
(Lonza Australia Pty Ltd., Mount Waverley, VIC, Australia), supplemented with 10% foe-
tal bovine serum (FBS; Interpath, Heidelberg West, VIC, Australia) and 100 U/mL of pen-
icillin and streptomycin (GibcoTM BRL, Scoresby, VIC, Australia) was used to culture 
MCF7 cell line at 37 °C in the presence of 5% CO2. 
3.3. Cell Viability Determination 
Cellular viability was determined using the alamarBlue (resazurin) assay [132–134]. 
Briefly, in a 96-well plate, 100 µL of the suspended MCF7 cells was seeded at 1 × 104/well, 
and incubated at 37 °C in the presence of 5% CO2 overnight to adhere. The cells were 
treated with different concentrations of CBD, chemotherapeutic drugs, and their combi-
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nations in different ratios, together with the vehicle control (0.5% dimethyl sulfoxide). Af-
ter 72 h, the medium was removed from the wells, and then 100 µL of alamarBlue (0.1 
mg/mL in FBS free media) solution was added to each well and incubated for 4 h at 37 °C 
in the presence of 5% CO2. Using a microplate spectrophotometer (BMG CLARIO star, 
Victoria, Australia), the fluorescence was measured at an excitation wavelength of 555 nm 
and an emission wavelength of 595 nm. Cell viability was determined as a percentage of 
vehicle-treated cells (control; 0.5% DMSO). 
3.4. Synergy Quantification of CBD and Standard Chemotherapeutics against MCF7 Human 
Breast Adenocarcinoma Cells 
The potential interactions between CBD and the chemotherapeutic drugs were ana-
lysed using the combination index (CI) model and the DrugComb portal [75]. CompuSyn 
version 2.0 (Biosoft, San Francisco, CA, USA) was used for the CI calculations based on 
the median-effect equation, which was derived from the mass–action law [135–137]. In the 
current study, nine pairwise combinations of chemotherapeutic drugs with CBD were 
studied in a constant ratio design, with a six-point dose–response curve in 1:2 serial dilu-
tion (n = 3), using the CI model (Chou–Talalay method) (Table 5) and 1:10 serially diluted 
chemotherapeutic drugs in the checkerboard design (n = 3) for better exploration of the 
interaction over a wider range of doses. The response data obtained from the CI model 
were further analysed in DrugComb, where the mean percentage of cell inhibition and 
the concentrations of the combined drugs were used as inputs for synergy scores in dif-
ferent models and combination sensitivity score (CSS) evaluation. 
Table 5. Molar ratios, concentrations, and codes of cannabidiol (CBD) combinations. 
Combination Code * 
Highest Concentration (µM) 
Molar Ratio (CBD:Drug) 
CBD Drug 
CXYZ19 15.9 0.9 18:1 
CXYZ28 31.8 0.8 40:1 
CXYZ37 47.7 0.7 68:1 
CXYZ46 63.6 0.6 106:1 
CXYZ55 79.5 0.5 159:1 
CXYZ64 95.4 0.4 238:1 
CXYZ73 111.3 0.3 371:1 
CXYZ82 127.2 0.2 636:1 
CXYZ91 143.1 0.1 1431:1 
*: C refers to CBD; XYZ indicates initials of the chemotherapeutic drugs; the two-digit numbers 
refer to the combination with the corresponding molar ratio. 
3.5. Flow Cytometric Analyses of Apoptosis in MCF7 Human Breast Adenocarcinoma Cells 
Using Annexin V-CF Blue and 7-Aminoactinomycin D (7AAD) 
The apoptotic profiles of MCF7 cells were examined using Abcam Apoptosis Detec-
tion Kit (#ab214663, Abcam, VIC, Australia) according to the manufacturer’s protocol, af-
ter 24 h of treatment with CBD, chemotherapeutic drugs, and their most synergistic com-
bination. Briefly, MCF7 cells were seeded at a density of 1 × 106 per mL in T75 cell culture 
flasks and treated with the vehicle control (0.5% DMSO), selected synergistic CBD+ 
chemotherapeutic drug combinations, and monotherapies (individual treatment with 
CBD or chemotherapeutic drugs). The cell culture media were collected after 24 h of treat-
ment, and cells were detached using 0.25% w/v of trypsin for 3 min at 37 °C. Trypsin was 
neutralised with an equal volume of 10% FBS-containing DMEM, and combined with the 
previously collected media. Cell pellets were collected by centrifugation at 500× g for 5 
min at room temperature (RT), rinsed twice in PBS, resuspended in 1 mL PBS, and centri-
fuged again for 5 min at 500× g. The cell pellets harvested from all treatment and control 
groups were instantaneously resuspended in 0.5 mL of 1X binding buffer, and 5 µL of 
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annexin V-CF blue and 7-AAD staining solutions were added to each 100 µL of cell sus-
pension. After 15 min of incubation in the dark, 400 µL of 1X binding buffer was added. 
The cells were then examined using an ACEA Biosciences NovoCyte 3000 flow cytometer 
(ACEA Biosciences Inc., San Diego, CA, USA). For analysis and processing, the NovoEx-
press (version 1.5.0, ACEA Biosciences Inc., USA) software was implemented, where cells 
were gated on FSC vs. SSC to exclude the cell debris and aggregates. The cells were then 
gated on a dot plot of Annexin V-CF in Pacific Blue vs. 7-AAD fluorescence in PerCP, with 
a quadrant placed indicating live cells (+Annexin V and −7-AAD) in the lower-left quad-
rant, early apoptotic cells (+Annexin V and −7-AAD) in the lower-right quadrant, late 
apoptotic cells (+Annexin V and +7-AAD) in the upper-right quadrant, and necrotic cells 
(−Annexin V and +7-AAD) in the upper-left quadrant. Cell percentage data from each 
quadrant after each treatment (n = 3) were exported to GraphPad Prism for statistical anal-
ysis and visualisation. Annexin V and 7-AAD (7-aminoactinomycin D) were combined to 
distinguish necrotic cells from early and late apoptotic cells. Annexin V binds to the phos-
phatidylserine (PS) phospholipids, which are translocated to the outer surface of cells dur-
ing apoptosis [138]. 7-AAD, on the other hand, is a fluorescent dye that intercalates in 
double-stranded DNA, with a high affinity for guanine–cytosine residues, and is used as 
a fluorescent DNA marker in flow cytometry and fluorescence microscopy [139,140]. The 
PerCP and Pacific Blue channels were used for Annexin V and 7-AAD, respectively, as 
the emission spectra of these dyes do not overlap; therefore, no compensation is necessary 
[68]. 
3.6. Bottom-Up Label-Free Quantification Proteomics Study of MCF7 Cell Lysates after 
Treatment with the Most Synergistic Combination 
3.6.1. Cell Culture, Treatment, and Protein Extraction 
MCF7 cells were seeded at a density of 1.0 × 106 per mL cells in T75 flasks and incu-
bated overnight at 37 °C in the presence of 5% CO2. The media were aspirated and re-
placed with fresh media containing 0.5% DMSO as the vehicle control, and the selected 
doses of chemotherapeutic drugs, CBD, and their synergistic combinations, in triplicate, 
and incubated for 24 h at 37 °C in the presence of 5% CO2. Each cell flask was treated with 
0.25% w/v trypsin for 3 min at 37 °C, and the cell culture media were collected. Trypsin 
was neutralised with an equal volume of 10% FBS-containing DMEM before mixing with 
the previously collected media. The cells were centrifuged at 500× g for 5 min at RT, and 
then the pellets were rinsed twice with ice-cold PBS and centrifuged again at 500× g for 5 
min. The cell pellets were then resuspended in 100 µL of lysis buffer including 1 µL of 
universal nuclease and fully mass spectrometry (MS)-compatible Halt™ Protease and 
Phosphatase Inhibitor Cocktail, EDTA-Free (Thermo Scientific, Waltham, MA, USA). The 
cells were pipetted up and down 10–15 times until the sample viscosity was reduced, and 
then placed on ice for 20 min. The lysate was then centrifuged at 14,000 rpm for 20 min at 
4 °C and collected. 
3.6.2. Protein Quantification 
The Pierce™ Rapid Gold BCA Protein Assay Kit (#A53226, Thermo Scientific, USA) 
was employed for the determination of protein concentration of the cell lysate, in tripli-
cate, against bovine serum albumin (BSA) standard, as per the manufacturer’s protocol. 
Briefly, 1 µL of each sample replicate was diluted 1:20 in water together with 20 µL of each 
standard, and then placed in a 96-well plate with 200 µL of working reagent per well. 
Samples were diluted until they were within the working range of 20–2,000 µg mL−1. The 
plate was mixed thoroughly on a plate shaker for 30 s and incubated at RT for 5 min, and 
then the absorbance was measured within 20 min at 480 nm using a microplate spectro-
photometer (BMG CLARIOstar, Melbourne, VIC, Australia). The blank absorbance was 
subtracted from all other readings of standards and samples, and sample concentration 
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was determined against the established BSA standard calibration curve. Samples were 
stored at −80 °C for further analysis. 
3.6.3. Preparation and Clean-Up of Peptides 
One-hundred-microgram protein samples were used for chemical and enzymatic 
sample processing using the EasyPep™ Mini MS Sample Prep Kit, as per the manufac-
turer’s protocol (Thermo Fisher Scientific, USA). The final volume was adjusted to 100 µL 
using lysis buffer in a microcentrifuge tube. The reduction and alkylation solutions (50 µL 
each) were added, gently mixed, and incubated at 95 °C using a heat block for 10 min. The 
samples were allowed to cool at RT, and then 50 µL of the reconstituted trypsin/lys-C 
protease mixture was added to each sample and incubated with shaking at 37 °C for 3 h. 
After incubation, 50 µL of digestion stop solution was added and mixed gently. Peptide 
clean-up columns were implemented to remove hydrophilic and hydrophobic contami-
nants. Clean peptide samples were dried using a vacuum centrifuge and resuspended in 
100 µL of 0.1% formic acid in water for LC–MS analysis, and then carefully placed in max-
imum recovery sample vials (Waters Corp, Milford, MA, USA). 
3.6.4. Label-Free Bottom-Up Quantification Proteomics Analysis via  
Nano-Ultra-High-Performance Liquid Chromatography Coupled with Quadruple  
Time-of-Flight Mass Spectrometry (Nano-UPLC-qTOF-MS) 
A nanoACQUITY UPLC system (Waters Corp., Milford, MA, USA) coupled with a 
Synapt G2-S high-definition mass spectrometer (HDMS) (Waters Corp., Manchester, UK) 
operating in positive electron spray ion mode (ESI+) and equipped with a hybrid quadru-
pole time of flight (qTOF) analyser was used to analyse tryptic peptides. A Waters Nano-
LockSpray Exact Mass Ionization Source was utilised to maintain mass accuracy. Briefly, 
100 fg mL-1 Glu-fibrinopeptide B (GFP) dissolved in 50% aqueous acetonitrile containing 
0.1% formic acid with a lock mass m/z of 785.84.26 was infused as a lock spray solution at 
0.5 µL min−1 and calibrated against a sodium iodide solution. For the chromatographic 
separation of peptides, the nanoEase M/Z BEH C18 (1.7 µm, 130 Å, 75 µm × 100 mm, Wa-
ters Corp., Milford, MA, USA) at 40 °C was utilised and coupled with a nanoEase M/Z 
Symmetry C18 Trap Column (100 Å , 5 µm, 180 µm × 20mm, Waters Corp., Milford, MA, 
USA). Milli-Q water and acetonitrile containing 0.1% formic acid were used as mobile 
phases A and B, respectively (LCMS grade, Merck, Germany). An injection volume of 1 
µL at a 300 nL min−1 flow rate was used throughout the 50 min gradient. Samples were 
injected into the trapping column at 5 µL min−1 at 99% mobile phase A for 3 min, before 
being eluted to the analytical column. An initial 1% of mobile phase B was ramped to 85% 
B over 50 min with the following gradient: 10% B at 2 min, 40% B at 40 min, and 85% B at 
42 min. All samples were kept at 4 °C and were injected in duplicates. The ion source block 
temperature was set to 80 °C, and capillary voltage was maintained at 3 kV. Ions were 
acquired with m/z between 50 and 2000, scanning time of 0.5 sec, sample cone voltage and 
source offset at 30 V, nanoflow gas at 0.3 Bar, purge gas at 20 Lh−1, and cone gas flow at 20 
L h−1. A data–independent acquisition (DIA) method by MSE multiplex mode was used 
for sample acquisition with a T-wave collision-induced dissociation cell filled with argon 
gas, using MassLynx Mass Spectrometry Software (Waters Corporation, Milford, MA, 
USA). 
3.6.5. Data Processing and Availability 
Progenesis QI software (Waters Corporation, Milford, MA, USA) was used to import 
and further process the MassLynx-acquired data. Automatic selection of alignment refer-
ences among QC samples was set, and peptides were identified against the UniProt hu-
man proteome database (October 2020 version) using the ion accounting method, with a 
250 kDa protein mass maximum. One fragment per peptide or one peptide per protein 
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together with 3 fragments per protein were set as ion matching requirements using rela-
tive quantification, implementing the Hi-N method (n = 3). Auto peptide and fragment 
tolerance, and less than 4% FDR, were set as search tolerance parameters. Peptides with 
absolute mass error >20 ppm or a single charge were further filtered out. Pairwise com-
parisons of the identified proteins in the treated groups were performed against the con-
trol group for cytotoxic potential exploration, while the most synergistic combination 
samples were compared against monotherapy-treated samples for the elucidation of pos-
sible synergistic mechanisms. In each experimental design, proteins with analysis of var-
iance (ANOVA)-derived p-values of at least≤ 0.05 and q-values ≤ 0.05, with a fold change 
≥2, were considered significant and included for further pathway analyses. Differentially 
expressed proteins identified by the quantitative processing of the LC–MS/MS analysis of 
the proteome tryptic digestion were analysed by STRING [80], Reactome [81], g:Profiler 
[82], and IMPaLA [83] to identify the relevant pathways responsible for the synergistic 
effect against MCF7 cells. The G: SCS algorithm was used for multiple testing corrections 
in the g:Profiler platform, with an adjusted p-value threshold of 0.05. The raw and pro-
cessed data have been deposited to the ProteomeXchange Consortium via the PRoteomics 
IDEntifications (PRIDE) repository [141], with the dataset identifiers PXD026587 and 
10.6019/PXD026331. 
3.7. Statistical Analysis 
All statistical comparisons were performed using GraphPad Prism Version 9 (San 
Diego, CA, USA), except for the shotgun proteomics study, where MetaboAnalyst 5.0 was 
used together with Progenesis QIP (Waters Corporation, Milford, MA, USA). The signifi-
cance was analysed via ANOVA and t-tests for multiple and pairwise comparisons, re-
spectively. Data were expressed as means  ±  SD. Differences of at least p  <  0.05 between 
the mean values in the experiments were considered statistically significant. 
4. Conclusion and Future Directions 
Synergistic interactions were observed between CBD and the five selected chemo-
therapeutic drugs at different molar ratios in MCF7 cells, using different synergy quanti-
tation models. We highlighted the promising molar ratios of CBD and chemotherapeutic 
drug combinations that were validated against different synergy metrics. CBD synergis-
tically enhanced the antiproliferative activity of the standard chemotherapeutic drugs by 
promoting apoptosis. Moreover, the presented pilot label-free quantification-driven pro-
teomics study highlighted the cytotoxic mechanisms of CBD against MCF7 cells, along 
with the underlying synergistic mechanisms of its combination with SN−38. However, 
further targeted proteomics studies with absolute quantification are warranted in order 
to validate the presented targets and pathways. Good tolerability and minimal adverse 
effects are reported for CBD in clinical trials (50–1000 mg/day up to 13 weeks), with an 
increased easing of legislation to approve CBD products. Nevertheless, further validation 
of the proposed combinations in normal, non-transformed breast epithelial cells is re-
quired. 
The present study highlights potential new opportunities in breast cancer treatment 
with other chemotherapeutic agents, such as CDK or topoisomerase inhibitors. For exam-
ple, we speculated the potential CBD combinations with CDK4/6 inhibitors such as 
abemaciclib, palbociclib, and ribociclib based on CBD-mediated inhibition of CDK-6 in 
MCF7 cells. The presented cytotoxic mechanisms of CBD are encouraging for further in-
vestigation of CBD’s interaction with hormonal therapies, including aromatase inhibitors 
(such as anastrozole, letrozole, and exemestane), selective oestrogen receptor modulators 
(SERM such as tamoxifen or toremifene), and new generations of drugs such as fulves-
trant and goserelin. 
Collectively, CBD presents an opportunity to potentially enhance the effectiveness of 
the breast cancer treatment regimens containing doxorubicin, docetaxel, paclitaxel, SN38, 
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and vinorelbine. Furthermore, the proposed combinations with CBD may be able to alle-
viate chemotherapy-induced adverse effects by reducing the dosage of chemotherapeutic 
drugs, or via CBD’s ameliorative or protective activities. However, further in vivo and 
clinical studies are warranted in order to validate these in vitro findings. 
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Abbreviations 
4. EBP1 Eukaryotic translation initiation factor 4E-binding protein 1 
5-HT1A Serotonin 1A receptor 
AKT Protein kinase B 
CBD Cannabidiol 
CB1 and CB2 Cannabinoid receptor 1 and 2 
CCL3 Chemokine (C-C motif) ligand 3 
CDK Cyclin-dependent kinase 
CSS Combination sensitivity score 
DOC Docetaxel 
DOX Doxorubicin 
EGFR Epidermal growth factor receptor 
ER+/− Oestrogen receptor-positive/negative 
ETC Electron transport chain 
FC Fold change 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GPR55 G protein-coupled receptor 55 
Id1 DNA-binding protein inhibitor ID-1 
HER2+ Human epidermal growth factor receptor 2 positive 
HER3 Human epidermal growth factor receptor 3 
HGNC HUGO Gene Nomenclature Committee 
MCM Minichromosome maintenance proteins 
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MIP-2 Macrophage Inflammatory Protein-2 
mTOR Mechanistic target of rapamycin 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
ROS Reactive oxygen species 
PPAR-γ Peroxisome proliferator-activated receptor gamma 
PTX Paclitaxel 
SN−38 7-Ethyl-10-hydroxycamptothecin 
TAM Tumour-associated macrophage 
TRPVs Family of transient receptor potential (TRP) ion channel 
TNBC Triple-negative breast cancer 
VIN Vinorelbine 
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